Cue Health Announces Appointment of Josh Ghaim, Ph.D. and Sachin Jain, M.D. to its Board of Directors
November 17 2022 - 4:15PM
Business Wire
Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology
company that puts diagnostic information at the center of care,
today announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D. have
joined its Board of Directors. Cue Health’s Board now consists of
seven directors, five of whom are independent.
“On behalf of the management team and Board, I’m pleased to
welcome both Josh and Sachin to the Cue team. We are excited to
have vast knowledge of health plans and payors as well as the
perspective of a medical doctor on Cue’s Board as we continue to
pursue our vision of making healthcare more convenient, accessible,
and timely by placing diagnostic information at the center of
care,” said Ayub Khattak, Chairman and CEO of Cue Health.
Dr. Ghaim, who joined Cue’s Board on July 21, 2022, is the
Founder and Managing Partner of Ignite Venture Studio, an
innovation accelerator that builds digital health, wellness and
beauty brands. Previously, he was Chief Technology Officer at
Johnson & Johnson Consumer Health and a member of the
Management Committee at Johnson & Johnson Consumer, Medical
Devices, and the Pharma R&D leadership team. Dr. Ghaim serves
on the Boards of Directors of Nonagon LTD, African Diaspora
Network, Ignite Growth Brands, and Infinite Looks Inc. He holds a
B.S. in chemistry from Indiana University and a Ph.D. in
biochemistry and molecular biology from the University of
Illinois.
Dr. Jain, who joined Cue’s Board on October 7, 2022, serves as
President and CEO of SCAN Group and an adjunct professor of
medicine at Stanford. Earlier in his career, he was the Chief
Executive Officer of CareMore and Aspire Health, the care delivery
divisions of Elevance, Inc; Chief Medical Information and
Innovation Officer at Merck; an attending physician at Boston VA
Medical Center; and a faculty member at Harvard's Medical and
Business Schools. He has served in leadership roles in the U.S.
Department of Health and Human Services. Dr. Jain is also a
contributor to Forbes and serves on the Boards of Directors
America’s Health Insurance Plans (AHIP), Biofourmis, and the
Make-A-Wish Foundation. Dr. Jain is an Aspen Institute Health
Innovator’s Fellow and holds his A.B., M.D., and MBA from Harvard
University.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company
that makes it easier for individuals to access health information
and places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without a prescription and physician
supervision. Outside the United States, Cue Health has received the
CE mark in the European Union, Interim Order authorization from
Health Canada, regulatory approval from India's Central Drugs
Standard Control Organization, and PSAR authorization from
Singapore’s Health Sciences Authority. Cue was founded in 2010 and
is headquartered in San Diego. For more information, please visit
www.cuehealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221117005354/en/
MEDIA INQUIRIES press@cuehealth.com
Cue Health (NASDAQ:HLTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cue Health (NASDAQ:HLTH)
Historical Stock Chart
From Jul 2023 to Jul 2024